Black Diamond Therapeutics Presented Novel Real-World Evidence Of The Evolving EGFR Mutation Landscape In NSCLC And The Opportunity For BDTX-1535 In An Oral Presentation At The 2024 AACR Annual Meeting
Black Diamond Therapeutics Presented Novel Real-World Evidence Of The Evolving EGFR Mutation Landscape In NSCLC And The Opportunity For BDTX-1535 In An Oral Presentation At The 2024 AACR Annual Meeting
Black Diamond Therapeutics 在 2024 年 AACR 年會上的口頭陳述中提供了新的真實世界證據，證明了 NSCLC 表皮生長因子突變格局的演變以及 BDTX-1535 的機會
- Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC
- Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R mutation, a setting characterized by shorter duration of response to osimertinib
- BDTX-1535 profile differentiated as the most advanced fourth-generation oral TKI in clinical development addressing the full spectrum of classical, non-classical, and C797S resistance EGFR mutations
- 現實世界的數據表明，在所有 eGFrm NSCLC 患者中，有 20-30% 存在非經典突變
- 新興數據顯示，非經典表皮生長因子突變可以與經典的 L858R 突變共同表達，這種環境的特徵是對奧西替尼的反應時間較短
- BDTX-1535 特徵脫穎而出，成爲臨床開發中最先進的第四代口服 TKI，可應對全方位的經典、非經典和 C797S 耐藥性 EGFR 突變
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。